A prevascularized subcutaneous device-less site for islet and cellular transplantation
暂无分享,去创建一个
Tatsuya Kin | Boris Gala-Lopez | Rena Pawlick | A. Shapiro | T. Kin | R. Pawlick | B. Gala-Lopez | Andrew R Pepper | A M James Shapiro | A. Pepper | Shaheed Merani | S. Merani
[1] D. Grainger,et al. All charged up about implanted biomaterials , 2013, Nature Biotechnology.
[2] P. Carlsson,et al. Increased Numbers of Low-Oxygenated Pancreatic Islets After Intraportal Islet Transplantation , 2011, Diabetes.
[3] 齋藤 敬弘. Reversal of diabetes by the creation of neo-islet tissues into a subcutaneous site using islet cell sheets , 2011 .
[4] A. Powers,et al. Revascularization of Transplanted Islets , 2008, Diabetes.
[5] James M. Anderson,et al. Foreign body reaction to biomaterials. , 2008, Seminars in immunology.
[6] A. Shapiro,et al. Five-year follow-up after clinical islet transplantation. , 2005, Diabetes.
[7] C. Ricordi,et al. Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device , 2006, Transplantation.
[8] K. Lafferty,et al. A comparative study of transplant sites for endocrine tissue transplantation in the pig. , 1986, The Australian journal of experimental biology and medical science.
[9] D. Harlan,et al. Current Advances and Travails in Islet Transplantation , 2009, Diabetes.
[10] Lihong V. Wang,et al. Functional photoacoustic microscopy for high-resolution and noninvasive in vivo imaging , 2006, Nature Biotechnology.
[11] W M Reichert,et al. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. , 1997, Journal of biomedical materials research.
[12] E. Ryan,et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.
[13] Kazuo Kobayashi,et al. Macrophages in inflammation. , 2005, Current drug targets. Inflammation and allergy.
[14] A. M. Shapiro,et al. Risk factors for islet loss during culture prior to transplantation , 2008, Transplant international : official journal of the European Society for Organ Transplantation.
[15] Camillo Ricordi,et al. Clinical islet transplantation: advances and immunological challenges , 2004, Nature Reviews Immunology.
[16] M. Unno,et al. Strategy for clinical setting in intramuscular and subcutaneous islet transplantation , 2014, Diabetes/metabolism research and reviews.
[17] W M Reichert,et al. Engineering the tissue which encapsulates subcutaneous implants. III. Effective tissue response times. , 1998, Journal of biomedical materials research.
[18] C. Ricordi,et al. Factors influencing Islet of Langerhans graft function and monitoring. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[19] G. Molema,et al. Neovascularization and vascular markers in a foreign body reaction to subcutaneously implanted degradable biomaterial in mice , 2004, Angiogenesis.
[20] W M Reichert,et al. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. , 1998, Journal of biomedical materials research.
[21] O. Korsgren,et al. Aspects of pancreatic islet transplantation in diabetes mellitus. , 1989, Bailliere's clinical gastroenterology.
[22] A. Rajab. Islet Transplantation: Alternative Sites , 2010, Current diabetes reports.
[23] J. Permert,et al. Optimising islet engraftment is critical for successful clinical islet transplantation , 2008, Diabetologia.
[24] Boris Gala-Lopez,et al. Revascularization of Transplanted Pancreatic Islets and Role of the Transplantation Site , 2013, Clinical & developmental immunology.
[25] A. Shapiro,et al. Optimal implantation site for pancreatic islet transplantation , 2008, The British journal of surgery.
[26] R. Soares,et al. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. , 2013, Life sciences.
[27] Shaoyi Jiang,et al. Zwitterionic hydrogels implanted in mice resist the foreign-body reaction , 2013, Nature Biotechnology.
[28] A. Shapiro,et al. Islet Transplantation and Beta Cell Replacement Therapy , 2007 .
[29] James M. Anderson,et al. Biological Responses to Materials , 2001 .
[30] P. Lacy,et al. Automated Islet Isolation From Human Pancreas , 1989, Diabetes.
[31] C. Verchere,et al. Advances and Challenges in Islet Transplantation: Islet Procurement Rates and Lessons Learned from Suboptimal Islet Transplantation , 2011, Journal of transplantation.
[32] P. Gianello,et al. Bioengineered Sites for Islet Cell Transplantation , 2013, Current Diabetes Reports.
[33] S Satomi,et al. Assessment for revascularization of transplanted pancreatic islets at subcutaneous site in mice with a highly sensitive imaging system. , 2011, Transplantation proceedings.
[34] B. Lévy,et al. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. , 2004, The American journal of pathology.
[35] J. Minna,et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.
[36] Daniel Nyqvist,et al. Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. , 2005, Diabetes.
[37] W Kenneth Ward,et al. A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis. , 2008, Journal of diabetes science and technology.